Schizophrenia and personality disorders had the highest burdens of disability among individuals with mental health or substance use disorders, according to a new analysis published in The Lancet Psychiatry.
In this Q&A, corresponding author Christoph U. Correll, MD, explains his meta-analysis that found the presence of metabolic syndrome is significantly associated with cognitive dysfunction in individuals with schizophrenia.
Positive and Negative Syndrome Scale total scores dropped an additional 11.6 points in patients with schizophrenia who received combination xanomeline-trospium, compared with placebo, according to a published study.
Switching to aripiprazole or ziprasidone could improve weight and other cardiometabolic outcomes in patients with serious mental illness, according to a systematic review and meta-analysis published online in Schizophrenia Bulletin.
When choosing an antipsychotic for acute treatment of psychosis, evaluating the drug's side effects is an important step, Dr. Stephen Marder said at a 26th Annual National Psychopharmacology Update session.
Metabolic syndrome, diabetes, and hypertension are linked with greater global cognitive impairment in people with schizophrenia, according to a systematic review and meta-analysis published online ahead of print in JAMA Psychiatry.
Long-acting injectable (LAI) paliperidone palmitate significantly improved outcomes in patients with schizophrenia despite duration of illness, but those with shorter illness duration showed the best improvement, a study found.
The use of CYP2D6 and CYP2C19 genotyping to guide antipsychotic prescribing did not improve drug persistence in patients with schizophrenia, according to a randomized clinical trial published online in JAMA Network Open.
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.